Browsing by Author "Rodig, Scott"

Now showing items 1-20 of 24

    • Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors 

      Akbay, E; Koyama, S.; Carretero, J.; Altabef, A.; Tchaicha, J. H.; Christensen, Camilla Laulund; Mikse, O. R.; Cherniack, Andrew David; Beauchamp, Ellen Monica; Pugh, T; Wilkerson, M. D.; Fecci, P; Butaney, M.; Reibel, J. B.; Soucheray, M.; Cohoon, T. J.; Janne, Pasi Antero; Meyerson, Matthew Langer; Hayes, D. N.; Shapiro, Geoffrey Ira; Shimamura, T; Sholl, Lynette Marie; Rodig, Scott J.; Freeman, Gordon James; Hammerman, Peter Seth; Dranoff, G; Wong, Kwok-Kin (American Association for Cancer Research (AACR), 2013)
      The success in lung cancer therapy with Programmed Death (PD)-1 blockade suggests that immune escape mechanisms contribute to lung tumor pathogenesis. We identified a correlation between Epidermal Growth Factor Receptor ...

    • Antileukemic Activity of Nuclear Export Inhibitors that Spare Normal Hematopoietic Cells 

      Etchin, Julia; Sun, Q; Kentsis, Alex; Farmer, A; Zhang, Z C; Sanda, Takaomi; Mansour, M R; Barcelo, C; McCauley, D; Kauffman, M; Shacham, S; Christie, A L; Kung, A L; Rodig, Scott J.; Chook, Y M; Look, A. Thomas (Nature Publishing Group, 2013)
      Drugs that target the chief mediator of nuclear export, chromosome region maintenance 1 protein (CRM1) have potential as therapeutics for leukemia, but existing CRM1 inhibitors show variable potencies and a broad range of ...

    • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer 

      Strickland, Kyle C.; Howitt, Brooke E.; Shukla, Sachet A.; Rodig, Scott; Ritterhouse, Lauren L.; Liu, Joyce F.; Garber, Judy E.; Chowdhury, Dipanjan; Wu, Catherine J.; D'Andrea, Alan D.; Matulonis, Ursula A.; Konstantinopoulos, Panagiotis A. (Impact Journals LLC, 2016)
      Immune checkpoint inhibitors (e.g., anti-PD-1 and anti-PD-L1 antibodies) have demonstrated remarkable efficacy against hypermutated cancers such as melanomas and lung carcinomas. One explanation for this effect is that ...

    • Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1 

      Howitt, Brooke Elizabeth; Shukla, Sachet; Sholl, Lynette Marie; Ritterhouse, Lauren Lee; Watkins, Jaclyn Christine; Rodig, Scott J.; Stover, Elizabeth Harmon; Strickland, Kyle Craig; D'Andrea, Alan David; Wu, Catherine Ju-Ying; Matulonis, Ursula Anne; Konstantinopoulos, Panagiotis (American Medical Association (AMA), 2015)
      Importance Immune checkpoint inhibitor therapy has shown benefit in various cancers, but their potential in endometrial cancer (EC) is unknown. Observations Prediction of neoantigen load was performed using sequencing ...

    • Autocrine Activation of the MET Receptor Tyrosine Kinase in Acute Myeloid Leukemia 

      Kentsis, Alex; Reed, Casie; Rice, Kim L.; Sanda, Takaomi; Rodig, Scott J.; Tholouli, Eleni; Christie, Amanda; Valk, Peter J.M.; Delwel, Ruud; Ngo, Vu; Kutok, Jeffery Lorne; Dahlberg, Suzanne E.; Moreau, Lisa A.; Byers, Richard J.; Christensen, James G.; Woude, George Vande; Licht, Jonathan D.; Kung, Andrew L.; Staudt, Louis M.; Look, A. Thomas (Nature Publishing Group, 2012)
      Although the treatment of acute myeloid leukemia (AML) has improved significantly, more than half of all patients develop disease that is refractory to intensive chemotherapy. Functional genomics approaches offer a means ...

    • The Biology and Treatment of EML4-ALK Non-Small Cell Lung Cancer 

      Sasaki, Takaaki; Rodig, Scott; Chirieac, Lucian; Janne, Pasi (Elsevier BV, 2010-07)
      The fusion between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) has recently been identified in a subset of non-small cell lung cancers (NSCLCs). EML4-ALK is most often ...

    • Collagen XXIII: A Potential Biomarker for the Detection of Primary and Recurrent Non–Small Cell Lung Cancer 

      Spivey, Kristin A.; Banyard, Jacqueline; Solis, Luisa M.; Wistuba, Ignacio I.; Barletta, Justine; Gandhi, Leena; Feldman, Henry; Rodig, Scott; Chirieac, Lucian; Zetter, Bruce (American Association for Cancer Research (AACR), 2010-05)
      Background Collagen XXIII is a transmembrane collagen previously shown to be upregulated in metastatic prostate cancer. This study’s purpose was to determine the protein expression of collagen XXIII in tumor tissues from ...

    • Comprehensive analyses of tumor immunity: implications for cancer immunotherapy 

      Li, Bo; Severson, Eric; Pignon, Jean-Christophe; Zhao, Haoquan; Li, Taiwen; Novak, Jesse; Jiang, Peng; Shen, Hui; Aster, Jon C.; Rodig, Scott; Signoretti, Sabina; Liu, Jun S.; Liu, X. Shirley (BioMed Central, 2016)
      Background: Understanding the interactions between tumor and the host immune system is critical to finding prognostic biomarkers, reducing drug resistance, and developing new therapies. Novel computational methods are ...

    • Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry 

      Kluk, Michael J.; Ashworth, Todd; Wang, Hongfang; Knoechel, Birgit; Mason, Emily F.; Morgan, Elizabeth A.; Dorfman, David; Pinkus, Geraldine; Weigert, Oliver; Hornick, Jason L.; Chirieac, Lucian R.; Hirsch, Michelle; Oh, David J.; South, Andrew P.; Leigh, Irene M.; Pourreyron, Celine; Cassidy, Andrew J.; DeAngelo, Daniel J.; Weinstock, David M.; Krop, Ian E.; Dillon, Deborah; Brock, Jane E.; Lazar, Alexander J. F.; Peto, Myron; Cho, Raymond J.; Stoeck, Alexander; Haines, Brian B.; Sathayanrayanan, Sriram; Rodig, Scott; Aster, Jon C. (Public Library of Science, 2013)
      Fixed, paraffin-embedded (FPE) tissues are a potentially rich resource for studying the role of NOTCH1 in cancer and other pathologies, but tests that reliably detect activated NOTCH1 (NICD1) in FPE samples have been ...

    • Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia 

      Treon, Steven; Tripsas, Christina K.; Meid, Kirsten; Warren, Diane; Varma, Gaurav; Green, Rebecca; Argyropoulos, Kimon V.; Yang, Guang; Cao, Yang; Xu, Lian; Patterson, Christopher J.; Rodig, Scott; Zehnder, James L.; Aster, Jon; Harris, Nancy; Kanan, Sandra; Ghobrial, Irene; Castillo, Jorge; Laubach, Jacob; Hunter, Zachary; Salman, Zeena; Li, Jianling; Cheng, Mei; Clow, Fong; Graef, Thorsten; Palomba, M. Lia; Advani, Ranjana H. (Massachusetts Medical Society, 2015-04-09)
      Background: MYD88(L265P) and CXCR4(WHIM) mutations are highly prevalent in Waldenström's macroglobulinemia. MYD88(L265P) triggers tumor-cell growth through Bruton's tyrosine kinase, a target of ibrutinib. CXCR4(WHIM) ...

    • Identification of ALK Gene Alterations in Urothelial Carcinoma 

      Bellmunt, Joaquim; Selvarajah, Shamini; Rodig, Scott; Salido, Marta; de Muga, Silvia; Costa, Irmgard; Bellosillo, Beatriz; Werner, Lillian; Mullane, Stephanie; Fay, André P.; O'Brien, Robert; Barretina, Jordi; Minoche, André E.; Signoretti, Sabina; Montagut, Clara; Himmelbauer, Heinz; Berman, David M.; Kantoff, Philip; Choueiri, Toni K.; Rosenberg, Jonathan E. (Public Library of Science, 2014)
      Background: Anaplastic lymphoma kinase (ALK) genomic alterations have emerged as a potent predictor of benefit from treatment with ALK inhibitors in several cancers. Currently, there is no information about ALK gene ...

    • Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma 

      Du, Ziming; Abedalthagafi, Malak; Aizer, Ayal A.; McHenry, Allison R.; Sun, Heather H.; Bray, Mark-Anthony; Viramontes, Omar; Machaidze, Revaz; Brastianos, Priscilla K.; Reardon, David A.; Dunn, Ian F.; Freeman, Gordon J.; Ligon, Keith L.; Carpenter, Anne E.; Alexander, Brian M.; Agar, Nathalie Y.; Rodig, Scott J.; Bradshaw, Elizabeth M.; Santagata, Sandro (Impact Journals LLC, 2015)
      There are no effective medical treatments for WHO grade III (anaplastic) meningioma. Patients with this high-grade malignancy have a median survival of less than two years. Therapeutics that modulate the mechanisms that ...

    • Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation 

      Van Allen, Eliezer Mendel; Golay, H. G.; Liu, Yan; Koyama, S.; Wong, Kwok-Kin; Taylor-Weiner, Amaro; Giannakis, Marios; Harden, M.; Rojas-Rudilla, V.; Chevalier, A.; Thai, T.; Lydon, C.; Mach, S.; Wong, J. A.; Rabin, A. R.; Helmkamp, J.; Sholl, Lynette Marie; Carter, Scott Lambert; Oxnard, Geoffrey Raymond; Janne, Pasi Antero; Getz, Gad A; Lindeman, Neal I.; Hammerman, Peter Seth; Garraway, Levi Alexander; Hodi, Frank Stephen; Rodig, Scott J.; Dranoff, G; Wong, Kwok-Kin; Barbie, David Allen (American Association for Cancer Research (AACR), 2015)
      PD-1 immune checkpoint blockade occasionally results in durable clinical responses in advanced metastatic cancers. However, mechanism-based predictors of response to this immunotherapy remain incompletely characterized. ...

    • Mutations in G protein β subunits promote transformation and kinase inhibitor resistance 

      Yoda, Akinori; Adelmant, Guillaume; Tamburini, Jerome; Chapuy, Bjoern; Shindoh, Nobuaki; Yoda, Yuka; Weigert, Oliver; Kopp, Nadja; Wu, Shuo-Chieh; Kim, Sunhee S; Liu, Huiyun; Tivey, Trevor; Christie, Amanda L; Elpek, Kutlu G; Card, Joseph; Gritsman, Kira; Gotlib, Jason; Deininger, Michael W; Makishima, Hideki; Turley, Shannon J.; Javidi-Sharifi, Nathalie; Maciejewski, Jaroslaw P; Jaiswal, Siddhartha; Ebert, Benjamin L.; Rodig, Scott J.; Tyner, Jeffrey W; Marto, Jarrod; Weinstock, David Marc; Lane, Andrew Alan (Nature Publishing Group, 2014)
      Activating mutations in genes encoding G protein α (Gα) subunits occur in 4-5% of all human cancers, but oncogenic alterations in Gβ subunits have not been defined. Here we demonstrate that recurrent mutations in the Gβ ...

    • Next-Generation cDNA Screening for Oncogene and Resistance Phenotypes 

      Shindoh, Nobuaki; Weigert, Oliver; Bird, Liat; Yoda, Akinori; Yoda, Yuka; Sullivan, Timothy J.; Lane, Andrew Alan; Kopp, Nadja; Rodig, Scott J.; Fox, Edward Alvin; Weinstock, David Marc (Public Library of Science, 2012)
      There is a pressing need for methods to define the functional relevance of genetic alterations identified by next-generation sequencing of cancer specimens. We developed new approaches to efficiently construct full-length ...

    • A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-rearranged Lung Adenocarcinomas by Standard Immunohistochemistry 

      Mino-Kenudson, Mari; Chirieac, Lucian; Law, Kenny; Hornick, Jason; Lindeman, Neal; Mark, Eugene; Cohen, David W.; Johnson, Bruce; Janne, Pasi; Iafrate, Anthony; Rodig, Scott (American Association for Cancer Research, 2010-03)
      Purpose Approximately 5% of lung adenocarcinomas harbor an EML4-ALK gene fusion and define a unique tumor group that may be responsive to targeted therapy. However ALK-rearranged lung adenocarcinomas are difficult to ...

    • An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma 

      Drier, Yotam; Cotton, Matthew J.; Williamson, Kaylyn E.; Gillespie, Shawn M.; Ryan, Russell J.H.; Kluk, Michael J.; Carey, Christopher D.; Rodig, Scott J.; Sholl, Lynette M; Afrogheh, Amir H.; Faquin, William C.; Queimado, Lurdes; Qi, Jun; Wick, Michael J.; El-Naggar, Adel K.; Bradner, James E.; Moskaluk, Christopher A.; Aster, Jon C.; Knoechel, Birgit; Bernstein, Bradley E. (2016)
      Translocation events are frequent in cancer and may create chimeric fusions or ‘regulatory rearrangements’ that drive oncogene overexpression. Here we identify super-enhancer translocations that drive overexpression of the ...

    • Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer 

      Bowman-Colin, Christian; Xia, B.; Bunting, S.; Klijn, C.; Drost, R.; Bouwman, P.; Fineman, L.; Chen, X.; Culhane, Aedin; Cai, H.; Rodig, Scott J.; Bronson, Roderick Terry; Jonkers, J.; Nussenzweig, A.; Kanellopoulou, C.; Livingston, David Morse (Proceedings of the National Academy of Sciences, 2013)
      Germ-line mutations in PALB2 lead to a familial predisposition to breast and pancreatic cancer or to Fanconi Anemia subtype N. PALB2 performs its tumor suppressor role, at least in part, by supporting homologous ...

    • A Peripheral Immune Signature of Responsiveness to PD-1 Blockade in Patients With Classical Hodgkin Lymphoma 

      Cader, Fathima Zumla; Hu, Xihao; Goh, Walter L.; Wienand, Kirsty; Ouyang, Jing; Mandato, Elisa; Redd, Robert; Lawton, Lee; Chen, Pei-Hsuan; Weirather, Jason L.; Schackmann, Ron C. J.; Li, Bo; Ma, Wenjiang; Armand, Philippe; Rodig, Scott; Neuberg, Donna; Liu, X. Shirley; Shipp, Margaret A.; shipp (Springer Science and Business Media LLC, 2020-08-10)
      PD-1 blockade is highly effective in classical Hodgkin lymphoma although the mechanism of action in this largely MHC class I-negative tumor remains undefined. Given this conundrum, we utilized the complementary approaches ...

    • RelA-Induced Interferon Response Negatively Regulates Proliferation 

      Kochupurakkal, Bose S; Wang, Zhigang C.; Hua, Tony; Culhane, Aedin; Rodig, Scott J.; Rajkovic-Molek, Koraljka; Lazaro, Jean-Bernard; Richardson, Andrea; Biswas, Debajit Kumar; Iglehart, James Dirk (Public Library of Science (PLoS), 2015)
      Both oncogenic and tumor-suppressor activities are attributed to the Nuclear Factor kappa B (NF-kB) pathway. Moreover, NF-kB may positively or negatively regulate proliferation. The molecular determinants of these opposing ...